Human Anti-CD23 / FCER2 / FCER2A Antibody Product Attributes
Tested Applications: Flow Cytometry.
Application Notes: 5 ul per test where one test represents staining of a cell sample in a final volume of approximately 100 uL. The number of cells within a sample must be experimentally determined, but ranges between 1x105 to 1x108 cells.
Clonality: Monoclonal Antibody
Anti-CD23 / FCER2 / FCER2A Antibody Clone: EBVCS-5
Clone EBVCS-5 Host and Isotype: Mouse IgG1 kappa
Buffer and Stabilizer: 10 mM NaH2PO4, 150 mM NaCl, 0.09% NaN3, 0.1% gelatin, pH7.2
Antibody Concentration: 5 uL /test
Storage Conditions: 2-8C protected from light. Stable for 12 Months. Do Not Freeze.
CD23 / FCER2 / FCER2A Previously Observed Antibody Staining Patterns
Observed Antibody Staining Data By Tissue Type:Variations in CD23 / FCER2 / FCER2A antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in germinal center cells in the lymph node, tonsil. More moderate antibody staining intensity was present in germinal center cells in the lymph node, tonsil. Low, but measureable presence of CD23 / FCER2 / FCER2A could be seen inmelanocytes in skin. We were unable to detect CD23 / FCER2 / FCER2A in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:Tissues from cancer patients, for instance, have their own distinct pattern of CD23 / FCER2 / FCER2A expression as measured by anti-CD23 / FCER2 / FCER2A antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
|Sample Type||breast cancer||carcinoid||cervical cancer||colorectal cancer||endometrial cancer||glioma||head and neck cancer||liver cancer||lung cancer||lymphoma||melanoma||ovarian cancer||pancreatic cancer||prostate cancer||renal cancer||skin cancer||stomach cancer||testicular cancer||thyroid cancer||urothelial cancer|
Knapp W, Dorken B, et al. eds. 1989. Leucocyte Typing IV: White Cell Differentiation Antigens. Oxford University Press. New York. Yukawa K, Kikutani H, Owaki H, Yamasaki K, Yokota A, Nakamura H, Barsumian EL, Hardy RR, Suemura M and Kishimoto T. 1987. J Immunol. 138(8): 2576-2580. Armant M, Ishihara H, Rubio M, Delespesse G and Sarfati M. 1994. J Exp Med. 1994. 180(3): 1005-1011. Belleau JT, Gandhi RK, McPherson HM and Lew DB. 2005. Clin Mol Allergy. 3:6. (Flow cytometry) Farren TW, Giustiniani J, Liu FT, Tsitsikas DA, Macey MG, Cavenagh JD, Oakervee HE, Taussig D, Newland AC, Calaminici M, Bensussan A, Jenner M, Gribben JB and Agrawal SG. 2011. Blood. 118(8): 2174-2183. (Flow cytometry) Cromvik J, Johnsson M, Vaht K, Johansson JE and Wenneras C. 2014. Immun Inflamm Dis. 2(2): 99-113. (Flow cytometry)
Limitations and Warranty
enQuire Bio's Human Anti-CD23 Monoclonal is available for Research Use Only. This antibody is guaranteed to work for a period of two years when properly stored.
There are no reviews yet.